表紙
市場調査レポート

世界のジェネリック医薬品産業の分析

Analyzing the Global Generics Industry 2014

発行 Aruvian's R'search 商品コード 301382
出版日 ページ情報 英文 475 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
世界のジェネリック医薬品産業の分析 Analyzing the Global Generics Industry 2014
出版日: 2014年08月01日 ページ情報: 英文 475 Pages
概要

ここ数年の主要医薬品の特許満了および近い将来に起こる特許満了によって、世界のジェネリック医薬品産業への注目が高まっています。

当レポートでは、世界のジェネリック医薬品産業について調査し、産業の定義、これまでの発展の経緯、産業統計、産業規模の分析、および地域別の産業区分などを提供しており、治療分野別による特許満了問題とそのジェネリック医薬品への影響の詳細な分析、産業の構造、市場参入とR&D動向、および主要市場の分析をまとめ、主要企業のプロファイルを交えて、概略以下の構成でお届けします。

エグゼクティブサマリー

世界のジェネリック医薬品産業の分析

  • 産業の定義
  • 産業の歴史的発展
  • 産業概要
  • 産業規模の分析(金額・数量)
  • 産業区分:地域別
  • 特許満了
  • 特許満了:治療分野別
  • 世界のジェネリック医薬品産業の構造
  • 市場参入
  • 産業における研究開発

世界のジェネリック医薬品産業:ポーターのファイブフォース戦略分析

  • イントロダクション
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競争企業間の敵対関係
  • 新規参入業者の脅威
  • 代替品の脅威

規制の枠組み&ジェネリック医薬品産業への影響

  • 欧州
  • 日本
  • 米国

産業動向&課題

  • 「ジェネリック医薬品支持」法律の増加
  • アウトソーシングの効果的な利用
  • 小分子ジェネリック薬剤の人気
  • バイオシミラーへの注目が高まる
  • 様々な未開拓のジェネリック医薬品市場における可能性
  • 医薬品に対する複数の特許保護
  • 製薬イノベーター企業のライフサイクル管理戦略の課題
  • 研究開発(R&D)生産性の低さ

業界の戦略

  • M&Aの増加
  • アウトソーシングの効果的な利用
  • ハッチ・ワクスマン法(the Hatch-Waxman Act)およびパラグラフIVの仕様
  • 公認ジェネリック医薬品/複製品の登場
  • 戦略的アライアンスの人気
  • 新興市場におけるプレゼンス

世界のジェネリック医薬品産業:主要市場の分析

  • ベルギー
  • カナダ
  • 中国
  • フランス
  • ドイツ
  • インド
  • イタリア
  • 日本
  • オランダ
  • スペイン
  • 英国
  • 米国

ジェネリック医薬品の価格・医療費償還:主要市場の分析

  • 概要
  • オーストラリア
  • オーストリア
  • 中国
  • チェコ共和国
  • フランス
  • ドイツ
  • ハンガリー
  • インド
  • イタリア
  • 日本
  • ノルウェー
  • ポーランド
  • ルーマニア
  • スペイン
  • スウェーデン
  • 英国
  • 米国
  • その他の諸国

世界のジェネリック医薬品産業予測

主要企業

  • Actavis
    • 企業プロファイル
    • 事業区分の分析
    • 主要製品&サービス
    • 治療の概要
    • 財務分析
    • SWOT分析
  • Bayer AG
  • 第一三共
  • Hospira Inc
  • Lupin
  • Mylan Inc.
  • Novartis AG
  • Par Pharmaceutical Companies, Inc.
  • Sanofi
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Limited
  • Apotex
  • Biogaran S.A.S.
  • China Grand Pharmaceutical and Healthcare Holdings Limited
  • Dr. Reddy's Laboratories Limited (DRL)
  • Esteve Group
  • 日医工
  • Perrigo Company PLC
  • ratiopharm Group
  • Sandoz
  • 沢井製薬

用語

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global generics industry. Over the years, the global generic drugs industry has grown strongly owing partly to the fact that the period for patent protection has gotten shorter with major blockbuster drugs losing their patent protection.

Furthermore, governments around the world have put in place many policies that are encouraging the growth of generic usage and regulations have also established pricing systems to promote the development of the generic drugs sector.

Aruvian Research analyzes the global generics industry in its research report Analyzing the Global Generics Industry. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report.

The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well.

An analysis of major markets is carried out through industry overview, industry value & volume analysis, industry segmentation by geography and an industry forecast. Key markets analyzed include Belgium, Canada, China, France, Germany, India, Italy, Japan, the Netherlands, Spain, the UK and the United States.

An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States.

An industry forecast of the global generics industry is included till 2017 through a value & volume forecast.

Major players in the industry are analyzed through a corporate profile, analysis of business segments, major products and services, therapeutic snapshot, financial analysis and a SWOT analysis as well. Major players analyzed in this report include Actavis, Bayer AG, Daiichi Sankyo, Hospira, Lupin, Mylan Inc, Novartis AG, Par Pharmaceutical Companies, Sanofi, STADA Arzneimittel AG, TEVA Pharmaceutical Industries, Apotex, DRL, Esteve Group, Sandoz, and many others.

Table of Contents

A. Executive Summary

B. Analyzing the Global Generics Industry

  • B.1 Industry Definition
  • B.2 Historical Development of the Industry
  • B.3 Industry Overview
  • B.4 Industry Value & Volume Analysis
  • B.5 Industry Segmentation by Geography
  • B.6 Patent Expiries
  • B.7 Patent Expiries by Therapeutic Areas
  • B.8 Global Generic Industry Structure
  • B.9 Market Entry
  • B.10 Research & Development in the Industry

C. Global Generics Industry: Porter's Five Forces Strategy Analysis

  • C.1 Introduction
  • C.2 Bargaining Power of Buyers
  • C.3 Bargaining Power of Suppliers
  • C.4 Competitive Rivalry in the Industry
  • C.5 Threat of New Entrants
  • C.6 Threat of Substitutes

D. Regulatory Framework & Impact on the Generics Industry

  • D.1 Europe
  • D.2 Japan
  • D.31 United States

E. Industry Trends & Challenges

  • E.1 'Pro-Generics' Legislation on the Rise
  • E.2 Popularity of Small Molecule Generic Drugs
  • E.3 Growing Focus on Biosimilars
  • E.4 Potential in Various Untapped Generics Markets
  • E.5 Multiple Patent Protections on Drugs
  • E.6 Challenge of Life Cycle Management Strategy of Pharma Innovators
  • E.7 Low Research & Development Productivity

F. Industry Strategies

  • F.1 Rise in Mergers & Acquisitions
  • F.2 Effectively Using Outsourcing
  • F.3 Hatch-Waxman Act and Paragraph IV Certifications
  • F.4 Emergence of Authorized Generics/Copies
  • F.5 Popularity of Strategic Alliances
  • F.6 Presence in Emerging Markets

G. Global Generics Industry: Analysis of Major Markets

  • G.1 Belgium
    • G.1.1 Industry Overview
    • G.1.2 Industry Value & Volume
    • G.1.3 Industry Segmentation by Geography
    • G.1.4 Industry Forecast
  • G.2 Canada
    • G.2.1 Industry Overview
    • G.2.2 Industry Value & Volume
    • G.2.3 Industry Segmentation by Geography
    • G.2.4 Industry Forecast
  • G.3 China
    • G.3.1 Industry Overview
    • G.3.2 Industry Value & Volume
    • G.3.3 Industry Segmentation by Geography
    • G.3.4 Industry Forecast
  • G.4 France
    • G.4.1 Industry Overview
    • G.4.2 Industry Value & Volume
    • G.4.3 Industry Segmentation by Geography
    • G.4.4 Industry Forecast
  • G.5 Germany
    • G.5.1 Industry Overview
    • G.5.2 Industry Value & Volume
    • G.5.3 Industry Segmentation by Geography
    • G.5.4 Industry Forecast
  • G.6 India
    • G.6.1 Industry Overview
    • G.6.2 Biologics Manufacturing
    • G.6.3 Market Opportunities
    • G.6.4 Industry Challenges
    • G.6.5 Regulatory Issues
    • G.6.5 Industry Forecast
  • G.7 Italy
    • G.7.1 Industry Overview
    • G.7.2 Industry Value & Volume
    • G.7.3 Industry Segmentation by Geography
    • G.7.4 Industry Forecast
  • G.8 Japan
    • G.8.1 Industry Overview
    • G.8.2 Industry Value & Volume
    • G.8.3 Industry Segmentation by Geography
    • G.8.4 Industry Forecast
  • G.9 Netherlands
    • G.9.1 Industry Overview
    • G.9.2 Industry Value & Volume
    • G.9.3 Industry Segmentation by Geography
    • G.9.4 Industry Forecast
  • G.10 Spain
    • G.10.1 Industry Overview
    • G.10.2 Industry Value & Volume
    • G.10.3 Industry Segmentation by Geography
    • G.10.4 Industry Forecast
  • G.11 United Kingdom
    • G.11.1 Industry Overview
    • G.11.2 Industry Value & Volume
    • G.11.3 Industry Segmentation by Geography
    • G.11.4 Industry Forecast
  • G.12 United States
    • G.12.1 Industry Overview
    • G.12.2 Industry Value & Volume
    • G.12.3 Industry Segmentation by Geography
    • G.12.4 Industry Forecast

H. Pricing and Reimbursement of Generics: An Analysis by Major Markets

  • H.1 Overview
  • H.2 Pricing & Reimbursement in Australia
    • H.2.1 Overview
    • H.2.2 Generics Pricing & Reimbursement Scenario
    • H.2.3 Trends & Challenges
  • H.3 Pricing & Reimbursement in Austria
    • H.3.1 Overview
    • H.3.2 Generics Pricing & Reimbursement Scenario
    • H.3.3 Trends
  • H.4 Pricing & Reimbursement in China
    • H.4.1 Overview
    • H.4.2 Generics Pricing & Reimbursement Scenario
    • H.4.3 Trends & Challenges
  • H.5 Pricing & Reimbursement in the Czech Republic
    • H.5.1 Overview
    • H.5.2 Generics Pricing & Reimbursement Scenario
    • H.5.3 Trends & Challenges
  • H.6 Pricing & Reimbursement in France
    • H.6.1 Overview
    • H.6.2 Generics Pricing & Reimbursement Scenario
    • H.6.3 Trends & Challenges
  • H.7 Pricing & Reimbursement in Germany
    • H.7.1 Overview
    • H.7.2 Generics Pricing & Reimbursement Scenario
    • H.7.3 Trends & Challenges
  • H.8 Pricing & Reimbursement in Hungary
    • H.8.1 Overview
    • H.8.2 Generics Pricing & Reimbursement Scenario
    • H.8.3 Trends & Challenges
  • H.9 Pricing & Reimbursement in India
    • H.9.1 Overview
    • H.9.2 Generics Pricing & Reimbursement Scenario
    • H.9.3 Trends & Challenges
  • H.10 Pricing & Reimbursement in Italy
    • H.10.1 Overview
    • H.10.2 Generics Pricing & Reimbursement Scenario
    • H.10.3 Trends & Challenges
  • H.11 Pricing & Reimbursement in Japan
    • H.11.1 Overview
    • H.11.2 Generics Pricing & Reimbursement Scenario
    • H.11.3 Trends & Challenges
  • H.12 Pricing & Reimbursement in Norway
    • H.12.1 Overview
    • H.12.2 Generics Pricing & Reimbursement Scenario
    • H.12.3 Trends
  • H.13 Pricing & Reimbursement in Poland
    • H.13.1 Overview
    • H.13.2 Generics Pricing & Reimbursement Scenario
    • H.13.3 Trends & Challenges
  • H.14 Pricing & Reimbursement in Romania
    • H.14.1 Overview
    • H.14.2 Generics Pricing & Reimbursement Scenario
    • H.14.3 Trends & Challenges
  • H.15 Pricing & Reimbursement in Spain
    • H.15.1 Overview
    • H.15.2 Generics Pricing & Reimbursement Scenario
    • H.15.3 Trends & Challenges
  • H.16 Pricing & Reimbursement in Sweden
    • H.16.1 Overview
    • H.16.2 Generics Pricing & Reimbursement Scenario
    • H.16.3 Challenges
  • H.17 Pricing & Reimbursement in United Kingdom
    • H.17.1 Overview
    • H.17.2 Generics Pricing & Reimbursement Scenario
    • H.17.3 Trends & Challenges
  • H.18 Pricing & Reimbursement in United States
    • H.18.1 Overview
    • H.18.2 Regulation
    • H.18.3 Health Insurance
    • H.18.4 Generics Pricing
    • H.18.5 Reimbursement Scenario
    • H.18.6 Trends & Case Studies
    • H.18.7 Challenges
  • H.19 Pricing & Reimbursement in Other Countries
    • H.19.1 Denmark
    • H.19.2 Finland

I. Global Generics Industry Forecast

J. Major Industry Players

  • J.1 Actavis
    • J.1.1 Corporate Profile
    • J.1.2 Business Segment Analysis
    • J.1.3 Major Products & Services
    • J.1.4 Therapeutic Snapshot
    • J.1.5 Financial Analysis
    • J.1.6 SWOT Analysis
  • J.2 Bayer AG
    • J.2.1 Corporate Profile
    • J.2.2 Business Segment Analysis
    • J.2.3 Major Products & Services
    • J.2.4 Financial Analysis
    • J.2.5 SWOT Analysis
  • J.3 Daiichi Sankyo Co., Ltd.
    • J.3.1 Corporate Profile
    • J.3.2 Business Segment Analysis
    • J.3.3 Major Products & Services
    • J.3.4 Financial Analysis
    • J.3.5 SWOT Analysis
  • J.4 Hospira Inc
    • J.4.1 Corporate Profile
    • J.4.2 Business Segment Analysis
    • J.4.3 Major Products & Services
    • J.4.4 Therapeutic Snapshot
    • J.4.5 Financial Analysis
    • J.4.6 SWOT Analysis
  • J.5 Lupin
    • J.5.1 Corporate Profile
    • J.5.2 Business Segment Analysis
    • J.5.3 Major Products & Services
    • J.5.4 Financial Analysis
    • J.5.5 SWOT Analysis
  • J.6 Mylan Inc.
    • J.6.1 Corporate Profile
    • J.6.2 Business Segment Analysis
    • J.6.3 Major Products & Services
    • J.6.4 Financial Analysis
    • J.6.5 SWOT Analysis
  • J.7 Novartis AG
    • J.7.1 Corporate Profile
    • J.7.2 Business Segment Analysis
    • J.7.3 Major Products & Services
    • J.7.4 Financial Analysis
    • J.7.5 SWOT Analysis
  • J.8 Par Pharmaceutical Companies, Inc.
    • J.8.1 Corporate Profile
    • J.8.2 Business Segment Analysis
    • J.8.3 Major Products & Services
    • J.8.4 Therapeutic Snapshot
    • J.8.5 Financial Analysis
    • J.8.6 SWOT Analysis
  • J.9 Sanofi
    • J.9.1 Corporate Profile
    • J.9.2 Business Segment Analysis
    • J.9.3 Major Products & Services
    • J.9.4 Financial Analysis
    • J.9.5 SWOT Analysis
  • J.10 STADA Arzneimittel AG
    • J.10.1 Corporate Profile
    • J.10.2 Business Segment Analysis
    • J.10.3 Major Products & Services
    • J.10.4 Therapeutic Snapshot
    • J.10.5 Financial Analysis
    • J.10.6 SWOT Analysis
  • J.11 Teva Pharmaceutical Industries Limited
    • J.11.1 Corporate Profile
    • J.11.2 Business Segment Analysis
    • J.11.3 Major Products & Services
    • J.11.4 Therapeutic Snapshot
    • J.11.5 Financial Analysis
    • J.11.6 SWOT Analysis
  • J.12 Apotex
  • J.13 Biogaran S.A.S.
  • J.14 China Grand Pharmaceutical and Healthcare Holdings Limited
  • J.15 Dr. Reddy's Laboratories Limited (DRL)
  • J.16 Esteve Group
  • J.17 Nichi-iko Pharmaceutical
  • J.18 Perrigo Company PLC
  • J.19 ratiopharm Group
  • J.20 Sandoz
  • J.21 Sawai Pharmaceutical Co., Ltd

K. Glossary of Terms

List of Figures

  • Figure 1: Review Process of a Generic Drug
  • Figure 2: Patent Certification Types by ANDA & US FDA Approval Processes
  • Figure 3: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
  • Figure 4: Value of the Global Generics Industry (in USD Million), 2008-2012
  • Figure 5: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2008-2012
  • Figure 6: Global Generics Market Segmentation by Geography (%), 2013
  • Figure 7: Revenues of Top 10 Drugs Facing Patent Expiries between 2010-2014 (in USD Million)
  • Figure 8: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
  • Figure 9: Market Share of Leading Generic Companies Worldwide (%), 2013
  • Figure 10: Comparison of Revenues of Leading Generic Companies (in USD Million), 2011-2012
  • Figure 11: Porter's Five Forces Analysis of the Global Generics Industry
  • Figure 12: Impact of Regulation on the Generics Market in the US
  • Figure 13: ANDA Filings, 2004-2012
  • Figure 14: ANDA Approvals, 2007-2012
  • Figure 15: Market Share of Generics in Selected Countries for Off-Patent Drugs Sector, 2011
  • Figure 16: Number of LCM Projects in Late-stage Development by Therapeutic Area, 2013
  • Figure 17: R&D Expenditure and Sales of Leading Pharma Companies (%), 2008-2013
  • Figure 18: Acquisitions by Matrix Labs
  • Figure 19: Region-wise Contribution to Growth of Leading Generic Companies, 2009-2014
  • Figure 20: Healthcare Financing by Selected Countries
  • Figure 21: Value of the Generics Market in Belgium (in USD Million), 2008-2012
  • Figure 22: Volume Growth of the Generics Market in Belgium (%), 2008-2012
  • Figure 23: Share of Belgium in the European Generics Industry (%), 2012
  • Figure 24: Forecast of the Generics Market in Belgium (in USD Million), 2012-2017
  • Figure 25: Volume Forecast of the Generics Market in Belgium (%), 2012-2017
  • Figure 26: Value of the Generics Market in Canada (in USD Million), 2008-2012
  • Figure 27: Volume Growth of the Generics Market in Canada (%), 2008-2012
  • Figure 28: Share of Canada in the Americas' Generics Industry (%), 2012
  • Figure 29: Forecast of the Generics Market in Canada (in USD Million), 2012-2017
  • Figure 30: Volume Forecast of the Generics Market in Canada (%), 2012-2017
  • Figure 31: Value of the Generics Market in China (in USD Million), 2008-2012
  • Figure 32: Volume Growth of the Generics Market in China (%), 2008-2012
  • Figure 33: Share of China in the Asia Pacific Generics Industry (%), 2012
  • Figure 34: Forecast of the Generics Market in China (in USD Million), 2012-2017
  • Figure 35: Volume Forecast of the Generics Market in China (%), 2012-2017
  • Figure 36: Value of the Generics Market in France (in USD Million), 2008-2012
  • Figure 37: Volume Growth of the Generics Market in France (%), 2008-2012
  • Figure 38: Share of France in the European Generics Industry (%), 2012
  • Figure 39: Forecast of the Generics Market in France (in USD Million), 2012-2017
  • Figure 40: Volume Forecast of the Generics Market in France (%), 2012-2017
  • Figure 41: Value of the Generics Market in Germany (in USD Million), 2008-2012
  • Figure 42: Volume Growth of the Generics Market in Germany (%), 2008-2012
  • Figure 43: Share of Germany in the European Generics Industry (%), 2012
  • Figure 44: Forecast of the Generics Market in Germany (in USD Million), 2012-2017
  • Figure 45: Volume Forecast of the Generics Market in Germany (%), 2012-2017
  • Figure 46: Value of the Generics Market in Italy (in USD Million), 2008-2012
  • Figure 47: Volume Growth of the Generics Market in Italy (%), 2008-2012
  • Figure 48: Share of Italy in the European Generics Industry (%), 2012
  • Figure 49: Forecast of the Generics Market in Italy (in USD Million), 2012-2017
  • Figure 50: Volume Forecast of the Generics Market in Italy (%), 2012-2017
  • Figure 51: Value of the Generics Market in Japan (in USD Million), 2008-2012
  • Figure 52: Volume Growth of the Generics Market in Japan (%), 2008-2012
  • Figure 53: Share of Japan in the Asia Pacific Generics Industry (%), 2012
  • Figure 54: Forecast of the Generics Market in Japan (in USD Million), 2012-2017
  • Figure 55: Volume Forecast of the Generics Market in Japan (%), 2012-2017
  • Figure 56: Value of the Generics Market in the Netherlands (in USD Million), 2008-2012
  • Figure 57: Volume Growth of the Generics Market in the Netherlands (%), 2008-2012
  • Figure 58: Share of Netherlands in the European Generics Industry (%), 2012
  • Figure 59: Forecast of the Generics Market in the Netherlands (in USD Million), 2012-2017
  • Figure 60: Volume Forecast of the Generics Market in the Netherlands (%), 2012-2017
  • Figure 61: Value of the Generics Market in Spain (in USD Million), 2008-2012
  • Figure 62: Volume Growth of the Generics Market in Spain (%), 2008-2012
  • Figure 63: Share of Spain in the European Generics Industry (%), 2012
  • Figure 64: Forecast of the Generics Market in Spain (in USD Million), 2012-2017
  • Figure 65: Volume Forecast of the Generics Market in Spain (%), 2012-2017
  • Figure 66: Value of the Generics Market in the UK (in USD Million), 2008-2012
  • Figure 67: Volume Growth of the Generics Market in the UK (%), 2008-2012
  • Figure 68: Share of the UK in the European Generics Industry (%), 2012
  • Figure 69: Forecast of the Generics Market in the UK (in USD Million), 2012-2017
  • Figure 70: Volume Forecast of the Generics Market in the UK (%), 2012-2017
  • Figure 71: Value of the Generics Market in the US (in USD Million), 2008-2012
  • Figure 72: Volume Growth of the Generics Market in the US (%), 2008-2012
  • Figure 73: Share of the US in the Global Generics Industry (%), 2012
  • Figure 74: Forecast of the Generics Market in the US (in USD Million), 2012-2017
  • Figure 75: Volume Forecast of the Generics Market in the US (%), 2012-2017
  • Figure 76: Healthcare Regulatory Agencies in China & their Responsibilities, 2012
  • Figure 77: Financing Law of Social Security (Loi de Financement de la Sécurité Sociale) in France, 2011
  • Figure 78: Impacts on Drug Prices in India, 2012
  • Figure 79: Stepped Price System in Norway, 2011
  • Figure 80: Private & Government Health Insurance in the US, 2012
  • Figure 81: Distribution Channel and Logistics of Generics in the US, 2012
  • Figure 82: Fee for Service, Preferred Provider Organization & Health Maintenance Organization in the US, 2012
  • Figure 83: Yearly Price Index Change of Prescription Drugs in the US (%), 2010-2012
  • Figure 84: Yearly Retail Price Index of Generic Drugs in the US (%), 2010-2012
  • Figure 85: Standard Medicare Part D Benefit Comparison of 2011 & 2020 in the US
  • Figure 86: Cost Sharing of Generic Drugs in the US (%), 2011-2020
  • Figure 87: Global Generics Industry Forecast (in USD Million), 2012-2017
  • Figure 88: Global Generics Industry Forecast by Volume (%), 2012-2017
  • Figure 89: Financial Performance of Actavis Plc (in USD Million), 2009-2013
  • Figure 90: Financial Performance of Bayer AG (in EURO Million), 2009-2013
  • Figure 91: Financial Performance of Daiichi Sankyo Company (in JPY Million), 2009-2013
  • Figure 92: Financial Performance of Hospira Inc. (in USD Million), 2009-2013
  • Figure 93: Financial Performance of Lupin (in INR Million), 2009-2013
  • Figure 94: Financial Performance of Mylan Inc (in USD Million), 2009-2013
  • Figure 95: Financial Performance of Novartis AG (in USD Million), 2009-2013
  • Figure 96: Financial Performance of Sanofi (in EURO Million), 2009-2013
  • Figure 97: Financial Performance of STADA (in EURO Million), 2008-2012
  • Figure 98: Financial Performance of Teva Pharmaceutical Industries (in USD Million), 2009-2013

List of Tables

  • Table 1: Value of the Global Generics Industry (in USD Million), 2008-2012
  • Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2008-2012
  • Table 3: Global Generics Industry, Segmentation by Geography (in USD Million), 2013
  • Table 4: Major Patent Expiries due by 2014
  • Table 5: Patent Expiries for Leading Biologic Drugs, 2010-2016
  • Table 6: Regulations for Usage of Generic Drugs in Selected EU Countries
  • Table 7: Incentives for Generic Drugs in Selected EU Countries
  • Table 8: Companies Moving towards Vertical Integration
  • Table 9: Major Authorized Generics, as of 2012
  • Table 10: Value of the Generics Market in Belgium (in USD Million), 2008-2012
  • Table 11: Volume Growth of the Generics Market in Belgium (%), 2008-2012
  • Table 12: Share of Belgium in the European Generics Industry (% & USD Million), 2012
  • Table 13: Forecast of the Generics Market in Belgium (in USD Million), 2012-2017
  • Table 14: Volume Forecast of the Generics Market in Belgium (%), 2012-2017
  • Table 15: Value of the Generics Market in Canada (in USD Million), 2008-2012
  • Table 16: Volume Growth of the Generics Market in Canada (%), 2008-2012
  • Table 17: Share of Canada in the Americas' Generics Industry (% & USD Million), 2012
  • Table 18: Forecast of the Generics Market in Canada (in USD Million), 2012-2017
  • Table 19: Volume Forecast of the Generics Market in Canada (%), 2012-2017
  • Table 20: Value of the Generics Market in China (in USD Million), 2008-2012
  • Table 21: Volume Growth of the Generics Market in China (%), 2008-2012
  • Table 22: Share of China in the Asia Pacific Generics Industry (% & USD Million), 2012
  • Table 23: Forecast of the Generics Market in China (in USD Million), 2012-2017
  • Table 24: Volume Forecast of the Generics Market in China (%), 2012-2017
  • Table 25: Value of the Generics Market in France (in USD Million), 2008-2012
  • Table 26: Volume Growth of the Generics Market in France (%), 2008-2012
  • Table 27: Share of France in the European Generics Industry (% & USD Million), 2012
  • Table 28: Forecast of the Generics Market in France (in USD Million), 2012-2017
  • Table 29: Volume Forecast of the Generics Market in France (%), 2012-2017
  • Table 30: Value of the Generics Market in Germany (in USD Million), 2008-2012
  • Table 31: Volume Growth of the Generics Market in Germany (%), 2008-2012
  • Table 32: Share of Germany in the European Generics Industry (% & USD Million), 2012
  • Table 33: Forecast of the Generics Market in Germany (in USD Million), 2012-2017
  • Table 34: Volume Forecast of the Generics Market in Germany (%), 2012-2017
  • Table 35: Value of the Generics Market in Italy (in USD Million), 2008-2012
  • Table 36: Volume Growth of the Generics Market in Italy (%), 2008-2012
  • Table 37: Share of Italy in the European Generics Industry (% & USD Million), 2012
  • Table 38: Forecast of the Generics Market in Italy (in USD Million), 2012-2017
  • Table 39: Volume Forecast of the Generics Market in Italy (%), 2012-2017
  • Table 40: Value of the Generics Market in Japan (in USD Million), 2008-2012
  • Table 41: Volume Growth of the Generics Market in Japan (%), 2008-2012
  • Table 42: Share of Japan in the Asia Pacific Generics Industry (% & USD Million), 2012
  • Table 43: Forecast of the Generics Market in Japan (in USD Million), 2012-2017
  • Table 44: Volume Forecast of the Generics Market in Japan (%), 2012-2017
  • Table 45: Value of the Generics Market in the Netherlands (in USD Million), 2008-2012
  • Table 46: Volume Growth of the Generics Market in the Netherlands (%), 2008-2012
  • Table 47: Share of Netherlands in the European Generics Industry (% & USD Million), 2012
  • Table 48: Forecast of the Generics Market in the Netherlands (in USD Million), 2012-2017
  • Table 49: Volume Forecast of the Generics Market in the Netherlands (%), 2012-2017
  • Table 50: Value of the Generics Market in Spain (in USD Million), 2008-2012
  • Table 51: Volume Growth of the Generics Market in Spain (%), 2008-2012
  • Table 52: Share of Spain in the European Generics Industry (% & USD Million), 2012
  • Table 53: Forecast of the Generics Market in Spain (in USD Million), 2012-2017
  • Table 54: Volume Forecast of the Generics Market in Spain (%), 2012-2017
  • Table 55: Value of the Generics Market in the UK (in USD Million), 2008-2012
  • Table 56: Volume Growth of the Generics Market in the UK (%), 2008-2012
  • Table 57: Share of the UK in the European Generics Industry (% & USD Million), 2012
  • Table 58: Forecast of the Generics Market in the UK (in USD Million), 2012-2017
  • Table 59: Volume Forecast of the Generics Market in the UK (%), 2012-2017
  • Table 60: Value of the Generics Market in the US (in USD Million), 2008-2012
  • Table 61: Volume Growth of the Generics Market in the US (%), 2008-2012
  • Table 62: Share of the US in the Global Generics Industry (% & USD Million), 2012
  • Table 63: Forecast of the Generics Market in the US (in USD Million), 2012-2017
  • Table 64: Volume Forecast of the Generics Market in the US (%), 2012-2017
  • Table 65: Healthcare Expenditure in Austria, 2012
  • Table 66: Austria's Box Model for Reimbursement
  • Table 67: Healthcare Expenditure in Czech Republic, 2012
  • Table 68: Healthcare Expenditure in France, 2012
  • Table 69: Healthcare Expenditure in Germany, 2012
  • Table 70: Healthcare Expenditure in Hungary, 2012
  • Table 71: Drug Prices in Jan Aushadhi Shops in India Compared to Market Prices, 2012
  • Table 72: Healthcare Expenditure in Italy, 2012
  • Table 73: Healthcare Expenditure in Japan, 2012
  • Table 74: Japan's Trend in Revision Rates of Reimbursement Prices, 1994-2012
  • Table 75: Reimbursement Categories of Medicines in Norway
  • Table 76: Healthcare Expenditure in Poland, 2012
  • Table 77: Healthcare Expenditure in Spain, 2012
  • Table 78: Healthcare Expenditure in Sweden, 2012
  • Table 79: Retail Sales Price in Sweden, 2012
  • Table 80: Patient Co-Payments in Sweden, 2012
  • Table 81: Healthcare Expenditure in the UK, 2012
  • Table 82: Average Retail Coinsurance Rates by Tier, (%), 2011
  • Table 83: Reimbursement Programs in the US
  • Table 84: State Discount Programs in the US, 2012
  • Table 85: Yearly Price Index Change of Prescription Drugs in the US (%), 2010-2012
  • Table 86: Yearly Retail Price Index of Generic Drugs in the US (%), 2010-2012
  • Table 87: Changes in Standard Benefit Parameters of Medicare Part D in the US (in USD), 2008-2012
  • Table 88: Cost Sharing of Generic Drugs in the US (%), 2011-2020
  • Table 89: Reimbursement Thresholds in Denmark, 2012
  • Table 90: Healthcare Expenditure in Finland, 2012
  • Table 91: Global Generics Industry Forecast (in USD Million), 2012-2017
  • Table 92: Global Generics Industry Forecast by Volume & Percentage Growth (%), 2012-2017
Back to Top